allogeneic CMV-specific T cells

Allogeneic CMV-specific T cells (also known as CYT-101) is an investigational, off-the-shelf, HLA-matched cell-based immunotherapy consisting of cytomegalovirus (CMV)-specific cytotoxic T lymphocytes derived from healthy donors. Developed by QIMR Berghofer Medical Research Institute and its spin-out company Cyteph, this adoptive T-cell therapy targets CMV antigens (such as pp65 and IE1) that are selectively expressed in glioblastoma multiforme (GBM) tumor cells but absent in healthy brain tissue. By leveraging the natural homing and cytotoxic capabilities of CMV-specific T cells, the therapy aims to eliminate GBM cells and prevent tumor recurrence. It is currently being evaluated in a Phase 1/2 clinical trial (NCT06157541) as a monotherapy and in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda) for the treatment of newly diagnosed or recurrent glioblastoma multiforme and grade 4 astrocytoma in CMV-seropositive adults.

Other names

allogeneic CMV-specific cytotoxic T lymphocytesallogeneic CMV-specific T-lymphocytesallogeneic cytomegalovirus-specific T cells